Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Earnings Results, Beats Estimates By $1.27 EPS

by · The Cerbat Gem

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) announced its quarterly earnings data on Friday. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($1.14) by $1.27, FiscalAI reports. The firm had revenue of $14.34 million for the quarter, compared to analyst estimates of $8.34 million.

Verrica Pharmaceuticals Trading Up 1.6%

VRCA traded up $0.06 on Friday, reaching $3.93. The stock had a trading volume of 47,549 shares, compared to its average volume of 246,827. The company has a market capitalization of $37.14 million, a price-to-earnings ratio of -0.47 and a beta of 1.70. Verrica Pharmaceuticals has a fifty-two week low of $3.28 and a fifty-two week high of $13.60. The firm has a 50-day moving average of $4.16 and a 200-day moving average of $5.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VRCA. Bank of America Corp DE raised its holdings in Verrica Pharmaceuticals by 347.5% in the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock valued at $101,000 after buying an additional 111,678 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Verrica Pharmaceuticals by 23.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock valued at $61,000 after acquiring an additional 26,308 shares during the period. Marshall Wace LLP acquired a new position in Verrica Pharmaceuticals in the 2nd quarter valued at approximately $66,000. Invesco Ltd. raised its stake in shares of Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock valued at $33,000 after acquiring an additional 29,256 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after purchasing an additional 44,275 shares during the period. Institutional investors and hedge funds own 42.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Verrica Pharmaceuticals currently has a consensus rating of “Reduce”.

View Our Latest Research Report on Verrica Pharmaceuticals

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.

Further Reading